Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CTNM · as of Mar 31, 2025
Ownership Breakdown
64
Institutional Holders
▲ 3 vs Q4
$106.74M
Total Inst. Value
▼ $124.37M vs Q4
37.39M
Shares Outstanding
freeFloat 73.81%
15.29M
13F Shares Held
▼ 494,942 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CTNM largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JOHNSON & JOHNSON pharmaceutical preparations | 1.98M | 7.65% | 7.65% | $13.81B | May 7, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.72M | 6.65% | 6.65% | $12.01B | May 15, 2025 | — held |
FRANKLIN RESOURCES INC pharmaceutical preparations | 1.58M | 6.09% | 6.09% | $11.00B | May 13, 2025 | ▲ 130.6K |
PERCEPTIVE ADVISORS LLC pharmaceutical preparations | 1.44M | 5.57% | 5.57% | $10.06B | Aug 6, 2025 | — held |
VERSANT VENTURE MANAGEMENT, LLC pharmaceutical preparations | 918.2K | 3.55% | 3.55% | $6.41B | May 7, 2025 | — held |
FMR LLC pharmaceutical preparations | 810.3K | 3.13% | 3.13% | $5.66B | May 12, 2025 | ▲ 118.4K |
VANGUARD GROUP INC pharmaceutical preparations | 803.4K | 3.11% | 3.11% | $5.61B | May 9, 2025 | ▼ 5.7K |
SECTORAL ASSET MANAGEMENT INC pharmaceutical preparations | 800.8K | 3.10% | 3.10% | $5.59B | May 15, 2025 | — held |
HHLR ADVISORS, LTD. pharmaceutical preparations | 669.3K | 2.59% | 2.59% | $4.67B | May 15, 2025 | — held |
RED TREE MANAGEMENT, LLC pharmaceutical preparations | 638.2K | 2.47% | 2.47% | $4.45B | May 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
13
Increased
+424.4K shares3
New Positions
first time holders17
Decreased
−375.8K shares0
Sold Out
fully exitedNet shares change (top 50)
+48.5K
+424.4K / −375.8K
Net new holders
-1
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CTNM insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
4
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lorrain Daniel S. Chief Scientific Officer | Jun 1, 2026 | Sale | 4,170 | $13.16 | $54.9K | 139.4K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | May 1, 2026 | Sale | 3,870 | $13.06 | $50.5K | 143.8K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | May 1, 2026 | Sale | 300 | $13.84 | $4.2K | 143.5K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Apr 6, 2026 | Sale | 4,170 | $13.43 | $56.0K | 147.7K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Mar 2, 2026 | Sale | 4,170 | $15.01 | $62.6K | 151.9K | Form 4 ↗ |
Watkins Tim CMO & Head of Development | Mar 2, 2026 | Sale | 3,611 | $15.02 | $54.2K | 0 | Form 4 ↗ |
Stengone Carmine N. CEO and President | Feb 24, 2026 | Sale | 4,400 | $16.02 | $70.5K | 15.0K | Form 4 ↗ |
Stengone Carmine N. CEO and President | Feb 25, 2026 | Sale | 2,700 | $16.02 | $43.2K | 15.0K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Feb 25, 2026 | Sale | 3,824 | $16.01 | $61.2K | 156.1K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Feb 24, 2026 | Sale | 4,300 | $16.03 | $68.9K | 156.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is primarily owned by institutional investors, who hold approximately 40.9% of total shares outstanding. Company insiders own approximately 26.19%, while retail and public investors account for the remaining 32.91%.
The largest institutional shareholder of Contineum Therapeutics, Inc. Class A Common Stock is JOHNSON & JOHNSON, holding approximately 1.98 million shares — equal to 7.65% of outstanding shares — as of March 31, 2025.
A total of 64 institutional investors currently hold CTNM stock, with a combined institutional value of approximately $106,737,281 as of the most recent 13F filing period.
Frequently asked questions
CTNM ownershipContineum Therapeutics, Inc. Class A Common Stock (CTNM) is primarily owned by institutional investors, who hold approximately 40.9% of shares. The largest shareholder is JOHNSON & JOHNSON with a 7.65% stake. Company insiders hold 26.19%. Data sourced from SEC Form 13F as of March 31, 2025.